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Objective: The mechanisms causing the presence of platelet-derived microparticles
in the circulation are unknown. In vitro platelets release platelet-derived micropar-
ticles in response to complement activation. This study evaluates the relationship
between complement activation and levels of circulating platelet-derived micropar-
ticles in patients undergoing cardiac surgery.
Methods: Prospectively, 71 patients were included who underwent elective coronary
artery bypass grafting with cardiopulmonary bypass. The patients were randomly
allocated to one of the 3 groups: uncoated oxygenator, UnModified Surface (n 25)
or oxygenator coated with either BioPassive Surface (n  25) or BioActive Surface
(n  21). Platelet-derived microparticles and terminal complement complexes were
determined before bypass and after induction of anesthesia, 15 minutes after the start
of cardiopulmonary bypass, at the end of cardiopulmonary bypass, and 30 minutes
after administration of protamine sulfate.
Results: Demographic and cardiopulmonary bypass data were similar for the 3
groups. At the end of cardiopulmonary bypass, platelet-derived microparticle num-
bers were decreased in all 3 groups. No significant differences were observed among
the groups at any sampling point. At the end of cardiopulmonary bypass, terminal
complement complex concentrations were increased in all groups (P  .001), and
significant differences among the groups were present (P  .002).
Conclusions: Despite significant complement activation, no increase in numbers of
circulating platelet-derived microparticles was found in the systemic blood of patients
undergoing cardiac surgery with cardiopulmonary bypass. Thus complement activation
in vivo does not necessarily affect generation of platelet-derived microparticles.
On activation and during apoptosis, platelets and other cells bud offsmall parts of their plasma membrane, the so-called micropar-ticles. Extensive in vitro studies have been reported on platelet-derived microparticles (PMPs).1,2 When platelets are stimulatedin vitro with agonists, such as a combination of -thrombin andcollagen, the complement complex C5b-9, or the Ca2 ionophore
A23187, they release large numbers of PMPs.1,3,4 PMPs possess platelet factor 3
activity; that is, they facilitate coagulation through exposure of negatively charged
phospholipids, thereby providing binding sites for activated coagulation factors V
(factor Va), VIIIa, IXa, and XIa1,2,5,6 and enabling the formation of tenase and
prothrombinase complexes.1,2,7
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Increased numbers of PMPs have been reported in the
circulation of patients with diabetes,8,9 patients undergoing
cardiopulmonary bypass (CPB),10,11 and patients with acute
coronary ischemia,12 heparin-induced thrombocytopenia,13
myocardial infarction,14 uremia,15 idiopathic thrombocyto-
penic purpura,16 disseminated intravascular coagulation,17
plasmapheresis,18 or meningococcal septic shock,19 which
are all diseases that have been associated with a thrombo-
embolic tendency. Increased numbers of PMPs have been
found also in the pericardial fluid of patients undergoing
surgical intervention with CPB.20
Despite the widespread presence of PMPs in the circu-
lation, however, the mechanisms causing their release in
vivo are still unknown. Complement activation is markedly
increased during CPB, whereas coatings are known to re-
duce complement activation. Generation of PMPs induced
by complement activation was anticipated. Therefore in the
present study the relationship between in vivo complement
activation and the concentrations of circulating PMPs was
evaluated in patients undergoing cardiac surgery with CPB
with noncoated oxygenators and coated oxygenators.
Materials and Methods
Patients
On approval of the Medical Ethics Committee of the Academic
Medical Center and obtainment of signed informed consent, we
prospectively included 71 patients who underwent elective coro-
nary artery bypass grafting with CBP. Inclusion criteria were age
21 to 75 years, elective coronary artery bypass surgery, ejection
fraction of greater than 30%, body surface area of greater than 1.66
m2, and a preoperative hemoglobin value of greater than 7.5
mmol/L. Exclusion criteria were combined valve surgery or aneu-
rysmectomy, redo operations, insulin-dependent diabetes mellitus,
creatinine plasma level of greater than 300 mol/L, preoperative
intra-aortic balloon pumping, preoperative use of nonsteroidal
anti-inflammatory drugs, preoperative use of warfarin, preopera-
tive immunosuppressive therapy of greater than 24 hours’ dura-
tion, allergic reactions, and chronic obstructive pulmonary disease.
The patients were randomly allocated to one of 3 groups (Table 1).
CPB
All extracorporeal bypass circuits consisted of a hollow-fiber ox-
ygenator (Affinity; Medtronic, Minneapolis, Minn). The oxygen-
ator was uncoated (ie, without surface modification, UnModified
Surface [UMS; n  25]) or coated with either BioPassive Surface
(BPS; n  25; Trillium, Medtronic) or BioActive Surface (BAS; n
 21; Carmeda, Medtronic). The additional noncoated compo-
nents of the extracorporeal circuit were identical for all patients
and included a soft-shell venous reservoir, 2 additional reservoirs,
an arterial line filter, a tubing system (Medtronic), and a roller
pump as an arterial blood pump (3M Sarns, Ann Arbor, Mich).
One of the additional reservoirs was used to collect the shed blood,
which was processed by a cell saver before being returned into the
systemic circulation after termination of the bypass procedure. The
other reservoir was used to collect left vent (systemic) blood,
which was returned into the systemic circulation through the
soft-shell venous reservoir during the bypass procedure. The ex-
tracorporeal system was primed with 500 mL of Ringer lactate
solution, 1 L of Haemaccell (Behring, Malburg, Germany), 100
mL of mannitol 20% (wt/vol), 50 mL of sodium bicarbonate 8.4%
(wt/vol), and 200 mL of aprotinin (2  106 KIU Trasylol; Bayer,
Leverkusen, Germany). Magnesium sulfate, 4 mmol/10 kg (ie, 24
   32 mmol) and 10,000 IU of bovine heparin (Leo Pharma-
ceutical Products, Weesp, The Netherlands) were added to the
priming solution. The total priming volume was 1.85 L. All pa-
tients received 300 IU/kg heparin (Leo Pharmaceutical Products)
before cannulation of the aorta. CPB was initiated when the
activated clotting time was 480 seconds or greater. During CPB,
the activated clotting time was maintained at greater than 480
seconds by means of administration of additional heparin when
required. Moderate hypothermia (30°C-34°C) was used for all
patients. Myocardial protection was achieved by using cold (4°C-
8°C) crystalloid cardioplegia solution (St Thomas). Shed blood in
the surgical field was processed with a cell saver (HaemoLite 2
plus; Haemonetics Corp, Braintree, Mass). Processed blood was
returned into the systemic circulation of the patients immediately
after CPB. After weaning from CPB and decannulation, heparin
was neutralized with protamine sulfate at a 1:1 ratio.
Collection of Blood Samples
Arterial blood samples were obtained before induction of anesthe-
sia, 15 minutes after the start of CPB, at the termination of CPB,
and 30 minutes after protamine administration. For comparison
between plasma samples, PMP numbers, platelet counts, and ter-
minal complement complex (TCC) concentrations were corrected
for hemodilution by hemoglobin concentration.
Cell Count
Blood samples for hemoglobin and platelet counts were collected
in 5-mL glass vacutainer tubes containing ethylenediamine tetra-
acetic acid (Becton Dickinson, San Jose, Calif) and analyzed on a
Celldyn 4000 (Abbot, Mijdrecht, The Netherlands).
TABLE 1. Demographic and CPB data
Surface modification of the oxygenator
UMS BPS BAS
Patient no. 25 25 21
Male/female 25/0 23/2 20/1
Age (y) 62.0 7.11 59.9 9.7 61.4 9.9
Weight (kg) 87.5 12.1 87.1 14.8 83.1 9.8
Body surface area (m2) 2.04 0.17 2.06 0.18 1.99 0.12
Hemoglobin (mmol/L) 8.5 0.6 8.4 0.7 8.3 0.5
Platelet count (109/L) 227 67.4 219 69 233 53
Cardiopulmonary
bypass (min)
93.5 21.8 85.1 21.4 95.4 24.2
Aortic crossclamping
time (min)
58.5 15.9 55.1 17.2 58.6 19.7
All data are presented as means  SD. No significant differences were
found among the groups for any of the variables.
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TCCs
Arterial blood (2 mL) was anticoagulated with 10 mmol/L ethyl-
enediamine tetra-acetic acid. Cell-free plasma aliquots (1 mL)
were prepared by means of centrifugation (11 minutes at 1100g
and 4°C) and stored at 80°C until use. TCC measures the TCC
bound to the S-protein, representing the soluble nonlytic form of
TCC. TCC was determined by means of enzyme-linked immuno-
assay (Quidel, San Diego, Calif).
PMPs
Arterial blood (4.5 mL) was collected into 3.2% trisodium citrate
(Becton Dickinson). Blood cells were removed by means of cen-
trifugation for 20 minutes at 1550g and room temperature, and
plasma aliquots (250 L) were snap-frozen in liquid nitrogen and
stored at 80°C until use. After thawing plasma aliquots on
melting ice, plasma was centrifuged for 30 minutes (17,570g and
20°C) to pellet the microparticles, as described previously.19-22
After removal of 225 L of (MP-free) plasma, the 25-mL mi-
croparticle-enriched plasma was diluted with 225 mL of phos-
phate-buffered saline (PBS; 154 mmol/L NaCl and 1.4 mmol/L
phosphate, pH 7.4) containing 10.9 mmol/L trisodium citrate.
Microparticles were resuspended and centrifuged (30 minutes at
17,570g and 20°C). Again, 225 L of the supernatant was re-
moved, and microparticles were resuspended in the remaining 25
L and diluted 4-fold with PBS/citrate buffer, of which 5 L was
used per flow cytometric determination.
Flow Cytometric Analysis
Microparticle samples were analyzed in a FACSCalibur flow cy-
tometer with CellQuest software (Becton Dickinson). PMPs were
identified on forward scatter, side scatter, and binding of both
phycoerythrin-labeled annexin V (PharMingen, San Jose, Calif)
and fluorescein isothiocyanate–labeled anti-CD61 (glycoprotein
IIIA; clone Y2/51, IgG1; Dako A/S, Glostrup, Denmark) to dis-
tinguish PMPs from events caused by noise. To identify annexin
V–positive microparticles, a fluorescence threshold was placed in
a microparticle sample prepared without addition of calcium to
correct for autofluorescence. To identify CD61-positive events,
microparticles were incubated with a similar concentration of
isotype-matched control antibody (fluorescein isothiocyanate–la-
beled IgG1; Becton Dickinson) to set the fluorescence threshold.
Microparticles (5 L) were diluted in 35 L of PBS containing 2.5
mmol/L CaCl2 (pH 7.4) and 5 L of 500-fold prediluted normal
mouse serum (Central Laboratory of the Netherlands Red Cross
Bloodtransfusion Service, Amsterdam, The Netherlands). After
incubation for 15 minutes at room temperature, annexin V (5 L)
plus anti-CD61 (5 L) or IgG1 control antibody was added. The
mixtures were incubated in the dark (15 minutes at room temper-
ature). Subsequently, 200 L of PBS/calcium buffer was added,
and the suspensions were centrifuged (30 minutes at 17,570g and
20°C). Finally, 200 L of (MP-free) suspension was removed. The
microparticles were diluted in 300 L of PBS/calcium buffer
before flow cytometry, and all samples were analyzed for 1
minute. To estimate the number of PMPs per liter of plasma, the
number of events (N) found in the upper right (marker and annexin
V positive) quadrant of the flow cytometric analysis (FL1 vs FL2)
was used in the following formula: Number/L  N  [100/5] 
[355/150]  [106/250].
Statistics
Data were analyzed by using SPSS, release 11.0 (SPSS, Chicago,
Ill). Demographic and CPB data are reported as means with SDs.
Outcome data (PMPs, platelets, and TCCs) were corrected for
hemodilution (hemoglobin) and are presented as medians with
interquartile ranges. For all outcome variables, statistical analyses
were performed on the change of that variable relative to the
baseline value (t 0) per patient. Statistical significance (P .05,
2-sided) is indicated. The sample size was chosen on the basis of
preliminary observations, indicating that approximately 25 pa-
tients per group would be sufficient to achieve statistically signif-
icant differences in blood activation between coated and noncoated
oxygenators. Comparisons over time within treatment groups were
made by applying the Wilcoxon signed-rank test to the (paired)
observations at baseline and at the end of CPB. Comparisons
between (treatment) groups were made by applying the Kruskal-
Wallis test to the change between the end of CPB and baseline.
The observations at 15 minutes after the start of CPB and at 30
minutes after protamine sulfate are presented for descriptive pur-
poses.
Results
Clinical Results
The coating groups (UMS, BPS, and BAS) were compared
for preoperative parameters, including body surface area,
age, sex, hemoglobin value, platelet count, and surgical data
(CPB time and aortic crossclamping time). No significant
differences were found among the groups for any of the
variables tested (Table 1). There were no differences among
the groups in hemoglobin concentrations and platelet counts
at any sampling time. Hemodilution was similar in the 3
coating groups: the decreases in hemoglobin concentrations
and platelet counts after the start of the CPB procedure were
most likely due to hemodilution of the systemic patient
blood by the priming volume of the extracorporeal circuit
and administration of the cardioplegia solution for myocar-
dial protection. In addition, in all 3 coating groups, a similar
decrease in platelet count was observed after administration
of protamine sulfate.
PMPs and Platelet Counts During CPB
The numbers of PMPs at baseline were similar among the 3
coating groups (Figure 1, A). Fifteen minutes after the start
of CPB, the PMP numbers decreased in all 3 groups, despite
correction for hemodilution. During CPB, the PMP numbers
slightly recovered, but at the end of bypass, they were still
less than before the start of CPB. At the end of bypass, there
was a significant decrease of PMPs in the UMS group (P 
.001) and the BPS group (P  .028) when compared with
baseline values. After administration of protamine sulfate,
PMP numbers again slightly decreased in all groups. Sig-
nificant differences were not observed among the groups at
any sampling point.
In contrast to PMP numbers, platelet counts significantly
increased during CPB when corrected for hemodilution
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(Figure 1, B; end of CPB: UMS group, P  0.004; BPS
group, P  .001, and BAS group, P  .003).
Complement Activation During CPB
Before CPB, complement activation was not detectable or
hardly detectable (Figure 2). Fifteen minutes after the start
of CPB, plasma concentrations of TCCs increased in all 3
coating groups, indicating complement activation. TCC
concentrations further increased during CPB and remained
high after protamine sulfate administration. At the end of
CPB, TCC concentrations were significantly increased in all
3 groups (P  .001) when compared with baseline values.
At the end of CPB, significant differences among the coat-
ing groups were present (P  .002). At the other sample
times, no significant differences among the coating groups
were found.
Discussion
This study shows that despite considerable activation of the
complement system in vivo, circulating PMP numbers did
not increase. These results were not anticipated because
earlier in vitro studies clearly showed that complement
activation triggers the release of PMPs.1,4,23-25 Our present
data, however, suggest that other mechanisms must be in-
volved in the release of microparticles in vivo. On the other
hand, we cannot exclude that complement activation might
contribute to microparticle release in other patient popula-
tions or that it might affect the release of microparticles in
concert with other stimuli.
Earlier studies reported that CPB triggers the formation
of PMPs both in vitro26 and in vivo.10,11 In contrast, we
found an intraoperative decrease in PMP numbers. Most
likely, this lack of increase is due to the many relatively
recent improvements of the extracorporeal circuits.27-29 Al-
ternatively, in the present study the pericardial blood was
not reinfused during the bypass procedure but rather after-
ward. Because pericardial blood contains relatively high
numbers of cell-derived microparticles itself and is highly
activated with regard to fibrinolysis and coagulation, one
could hypothesize that by not returning this blood into the
systemic circulation during bypass, one of the triggers for
(systemic) blood activation has been eliminated. The same
Figure 1. Systemic concentrations of PMPs and platelet counts in patients undergoing CPB. Concentrations of
PMPs and platelet counts before bypass and after induction of anesthesia (baseline value; pre), 15 minutes after
the start of bypass (15'CPB), at the end of bypass and after release of the aortic crossclamp (end CPB), and 30
minutes after administration of protamine sulfate (30'prot) are shown. The measurements were made in 25 patients
treated with an uncoated oxygenator (ie, without Surface Modification, UMS group, open bars), 25 patients treated
with an oxygenator coated with a BioPassive Surface (BPS group, shaded bars), and 21 patients treated with an
oxygenator coated with a BioActive Surface (BAS group, striped bars). PMP concentrations (A) and platelet counts
(B) were determined as described in the “Methods” section. No significant differences were present among the
3 oxygenator groups. Medians and interquartile ranges are presented.
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holds for platelet activation. Whereas earlier studies re-
ported extensive platelet activation during CPB, more re-
cent studies showed less platelet activation.27,30 For in-
stance, Kestin and colleagues30 reported that platelets from
the systemic circulation of patients undergoing CPB showed
normal reactivity in vitro, had no loss of surface glycopro-
tein complexes Ib-IX and IIb-IIIa, and had hardly degranu-
lated.
In contrast, pericardial blood contains relatively high
numbers of PMPs and erythrocyte-derived micropar-
ticles.20,27 Whether local complement activation (ie, in this
wound blood) contributes to the release of PMPs cannot be
excluded.
In the present study this shed blood was processed by a
cell saver before being returned to the systemic circulation
after the bypass procedure had been terminated. This treat-
ment excludes the possibility that systemic blood activation
during the bypass procedure is caused by reinfusion of the
processed shed blood. On the other hand, we cannot exclude
that this reinfusion contributes to blood activation after
bypass.
Taken together, although the release of microparticles in
vitro from platelets is initiated by complement activation,
we found no evidence for a relationship between comple-
ment activation and the concentrations of PMPs in systemic
blood from patients undergoing CPB. We conclude that
complement activation in vivo does not importantly affect
the generation of PMPs.
We thank all our colleagues who supported this study and in
particular M. C. L. Schaap, R. Baak-Pablo, C. Hau, and H. Everts
for excellent technical assistance.
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